AstraZeneca Results Presentation Deck
Rare Disease
Total Revenue $3.1bn; +9% pro rata¹ FY 2021
Growth across all regions
Pro rata growth, 2021¹
2,000
1,800
1,600
1,400
1,200
1,000
800
600
400
200
+8%
+9%
hi..
+11%
+18%
US
FY 2020² FY 2021
EU
EROW
EM
3,500
3,000
2,500
2,000
1,500
1,000
500
0
Rare Disease performance
C5 Franchise (Soliris + Ultomiris) +11% Q4; +8% pro rata FY 2021²;
+11%
+9%¹
Q4 2020² Q4 2021 FY 2020² FY 2021
• Soliris: double-digit volume growth in
Neurology; Q4 benefitted from tender
market order timing
Soliris Ultomiris Strensiq Kanuma Andexxa
• Ultomiris: continued conversion in PNH,
aHUS despite COVID-19 impact; 14 new
country launches in FY 2021
●
Strensiq: growth driven by increased
demand in US
• Kanuma: strong revenue growth driven
by ex-US demand
• Andexxa: strong revenue growth in EU,
offset by COVID-related hospital access
challenges in the US
Opportunity for geographic expansion leveraging AstraZeneca's footprint
28
1. FY 2021 revenues from date of acquisition closing, 21 July 2021 through 31 December 2021; pro forma growth rates calculated by comparison post-acquisition revenues with the corresponding prior year revenues adjusted pro-
rata to match the post-acquisition period. 2. Inclusive of total revenues previously reported by Alexion and not adjusted for consistency with AstraZeneca's accounting policies, not audited and not included in AstraZeneca's FY
2021 results.View entire presentation